• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

帕博利珠单抗-阿昔替尼诱发的转移性肾癌患者肿瘤溶解综合征

Pembrolizumab-axitinib-induced tumor lysis syndrome in a patient with metastatic renal cancer.

作者信息

Shah Manan, Jain Sanjay, Abe Temidayo, Surapaneni Phani Keerthi, Bhatia Kapil

机构信息

Internal Medicine Morehouse School of Medicine Grady Memorial Hospital Atlanta Georgia.

Hematology-Oncology Morehouse School of Medicine Grady Memorial Hospital Atlanta Georgia.

出版信息

Clin Case Rep. 2020 Feb 15;8(4):704-708. doi: 10.1002/ccr3.2737. eCollection 2020 Apr.

DOI:10.1002/ccr3.2737
PMID:32274041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7141709/
Abstract

Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understanding of tumor lysis syndrome specially in solid tumors and will help in developing multidisciplinary treatment and prophylaxis strategies for this uncommon, but potentially fatal complication.

摘要

肿瘤溶解综合征在实体瘤中并不常见，但随着免疫疗法（检查点抑制剂）的使用，其发生率正在上升。医生在治疗接受免疫疗法的患者时需要采取充分的预防措施。我们病例报告的结果将有助于提高我们目前对肿瘤溶解综合征的认识，特别是在实体瘤方面，并将有助于制定针对这种罕见但可能致命的并发症的多学科治疗和预防策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c22/7141709/7f7a5b2340e4/CCR3-8-704-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c22/7141709/7f7a5b2340e4/CCR3-8-704-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c22/7141709/7f7a5b2340e4/CCR3-8-704-g001.jpg

相似文献

1
Pembrolizumab-axitinib-induced tumor lysis syndrome in a patient with metastatic renal cancer.帕博利珠单抗-阿昔替尼诱发的转移性肾癌患者肿瘤溶解综合征
Clin Case Rep. 2020 Feb 15;8(4):704-708. doi: 10.1002/ccr3.2737. eCollection 2020 Apr.
2
Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.帕博利珠单抗联合阿昔替尼用于转移性肾细胞癌二线及后续治疗的疗效
Clin Genitourin Cancer. 2023 Apr;21(2):221-229. doi: 10.1016/j.clgc.2023.01.002. Epub 2023 Jan 12.
3
Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.曲妥珠单抗和帕妥珠单抗治疗转移性乳腺癌后发生肿瘤溶解综合征：一例报告
J Med Case Rep. 2016 Jun 16;10:178. doi: 10.1186/s13256-016-0969-5.
4
Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases.帕博利珠单抗联合阿昔替尼治疗转移性肾集合管细胞癌的疗效：两例报告
IJU Case Rep. 2022 Sep 26;5(6):438-441. doi: 10.1002/iju5.12504. eCollection 2022 Nov.
5
Beyond the Expectation: Pembrolizumab-Associated Tumor Lysis Syndrome in Metastatic Gastric Adenocarcinoma.超乎预期：帕博利珠单抗相关的转移性胃腺癌肿瘤溶解综合征
Cureus. 2023 Oct 31;15(10):e48024. doi: 10.7759/cureus.48024. eCollection 2023 Oct.
6
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib.帕博利珠单抗联合阿昔替尼治疗转移性肾细胞癌患者发生 Takotsubo 综合征。
Immunotherapy. 2022 Nov;14(16):1297-1305. doi: 10.2217/imt-2022-0013. Epub 2022 Nov 21.
7
Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.实体瘤中的急性肿瘤溶解综合征——一例病例报告及文献综述
Cancer Chemother Pharmacol. 2003 Mar;51(3):187-92. doi: 10.1007/s00280-002-0556-x. Epub 2003 Feb 28.
8
Tumor Lysis Syndrome: A Rare Complication of Chemotherapy for Metastatic Breast Cancer.肿瘤溶解综合征：转移性乳腺癌化疗的一种罕见并发症。
Cureus. 2019 Feb 7;11(2):e4024. doi: 10.7759/cureus.4024.
9
Spontaneous Tumor Lysis Syndrome in Small-Cell Lung Cancer: A Rare Complication.小细胞肺癌中的自发性肿瘤溶解综合征：一种罕见的并发症。
World J Oncol. 2015 Oct;6(5):464-471. doi: 10.14740/wjon946w. Epub 2015 Oct 26.
10
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.2021 年更新版欧洲泌尿外科学会肾癌指南：免疫检查点抑制剂联合治疗用于治疗初治转移性透明细胞肾细胞癌，是标准治疗方案。
Eur Urol. 2021 Oct;80(4):393-397. doi: 10.1016/j.eururo.2021.04.042. Epub 2021 May 29.

引用本文的文献

1
Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study.免疫检查点抑制剂相关肿瘤溶解综合征：一项真实世界药物警戒研究。
Front Pharmacol. 2021 Sep 23;12:679207. doi: 10.3389/fphar.2021.679207. eCollection 2021.

本文引用的文献

1
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.派姆单抗联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
2
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.新型抗 PD-L1 抗体avelumab（MSB0010718C）在人肿瘤细胞上的抗体依赖细胞细胞毒性活性。
Cancer Immunol Res. 2015 Oct;3(10):1148-1157. doi: 10.1158/2326-6066.CIR-15-0059. Epub 2015 May 26.
3
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
癌症患者对抗PD-L1抗体MPDL3280A反应的预测性相关因素。
Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
4
Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature.实体瘤中的肿瘤溶解综合征：文献综述
Rare Tumors. 2014 Jun 13;6(2):5389. doi: 10.4081/rt.2014.5389. eCollection 2014 May 13.
5
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.CTLA-4 在原发性黑素瘤细胞系上的结合诱导抗体依赖性细胞细胞毒性和 TNF-α 的产生。
J Transl Med. 2013 May 1;11:108. doi: 10.1186/1479-5876-11-108.
6
Onco-nephrology: tumor lysis syndrome.肿瘤肾病学：肿瘤溶解综合征。
Clin J Am Soc Nephrol. 2012 Oct;7(10):1730-9. doi: 10.2215/CJN.03150312. Epub 2012 Aug 9.
7
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.一名接受甲苯磺酸索拉非尼治疗的晚期肝细胞癌患者出现大量肿瘤溶解，且未发生肿瘤溶解综合征。
Intern Med. 2010;49(11):991-4. doi: 10.2169/internalmedicine.49.3153. Epub 2010 Jun 1.
8
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.恶性肿瘤成人和儿童肿瘤溶解综合征（TLS）风险评估和预防推荐：专家 TLS 小组共识。
Br J Haematol. 2010 May;149(4):578-86. doi: 10.1111/j.1365-2141.2010.08143.x. Epub 2010 Mar 16.
9
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.儿童及成人肿瘤溶解综合征管理指南：循证综述
J Clin Oncol. 2008 Jun 1;26(16):2767-78. doi: 10.1200/JCO.2007.15.0177.
10
Tumour lysis syndrome: new therapeutic strategies and classification.肿瘤溶解综合征：新的治疗策略与分类
Br J Haematol. 2004 Oct;127(1):3-11. doi: 10.1111/j.1365-2141.2004.05094.x.